Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.
EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL
EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
Now Viewing
EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)
EP: 7.CAR T-Cell Therapy for Patients With R/R FL
EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Related Videos
Related Content
